Latest Breaking News On - Arunj sanyal - Page 4 : comparemela.com

Phase 2 Substudy Shows Retatrutide Use Could Contribute to NAFLD Resolution

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

Researchers identify a potential new drug for NASH-related fibrosis

Researchers at the University of California San Diego School of Medicine have led a study to examine a potential new treatment option for patients with nonalcoholic steatohepatitis (NASH)-related fibrosis.

Potential New Treatment Identified for Liver Disease: Study

American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium

/PRNewswire/ Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent.

Pegozafermin improves fibrosis, shows promise as 'mainstay treatment' for NASH

Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress. “As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,